Arigene to terminate tender offer for all of Trimeris' outstanding shares of common stock
Trimeris, Inc. today announced that in connection with the Agreement and Plan of Merger dated October 2, 2009, as amended, by and among Trimeris, Arigene Co., Ltd. and RTM Acquisition Company, Arigene has informed Trimeris through counsel that Arigene intends to terminate the tender offer for all of Trimeris' outstanding shares of common stock because Arigene was unable to secure sufficient financing for purposes of funding the tender offer.
Sanofi-aventis announced on January 24 that it has extended its tender offer for all outstanding shares of common stock of Genzyme Corporation at $69.00 per share, net to the seller in cash, without interest and less any required withholding taxes.